Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr127.60 SEK
Change Today -2.60 / -2.00%
Volume 179.4K
As of 8:25 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

meda ab-a shs (MEDAA) Snapshot

Open
kr129.00
Previous Close
kr130.20
Day High
kr129.00
Day Low
kr127.00
52 Week High
04/13/15 - kr152.00
52 Week Low
10/16/14 - kr85.61
Market Cap
46.7B
Average Volume 10 Days
705.2K
EPS TTM
kr1.46
Shares Outstanding
365.5M
EX-Date
05/7/15
P/E TM
87.4x
Dividend
kr2.50
Dividend Yield
1.96%
Current Stock Chart for MEDA AB-A SHS (MEDAA)

Related News

No related news articles were found.

meda ab-a shs (MEDAA) Related Businessweek News

No Related Businessweek News Found

meda ab-a shs (MEDAA) Details

Meda AB operates as a specialty pharmaceutical company worldwide. It manufactures and sells specialty pharmaceutical products, branded generics, over-the-counter drugs, and other products in various therapy areas, such as respiratory, dermatology, gastroenterology, cardiology, pain and inflammation, and CNS, as well as metabolism/vitamins. The company markets and sells its products through distributors in approximately 150 countries. Meda AB is headquartered in Solna, Sweden.

4,516 Employees
Last Reported Date: 04/8/15

meda ab-a shs (MEDAA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr17.0M
Compensation as of Fiscal Year 2014.

meda ab-a shs (MEDAA) Key Developments

Meda To Reportedly Sell Meda Pharmaceuticals

Meda AB (OM:MEDA A) intends to sell Meda Pharmaceuticals Inc. Meda is exploring options to sell Meda Pharmaceuticals, which could be worth about $1 billion, Bloomberg reported, citing people familiar with the matter. Meda plans to use the funds to reduce debt and seek other acquisitions, Bloomberg said. Rothschild is advising Meda on the sale process. Reuters added that Meda could not immediately be reached for comment outside regular business hours.

Meda AB Announces Earnings Results for the Second Quarter and Six Months Ended June 2015

Meda AB announced earnings results for the second quarter and six months ended June 2015. For the six months, the company reported net sales reached SEK 9,735 million against SEK 6,842 million a year ago, corresponding to an increase of 42%, 31% at constant exchange rates compared to the previous year. EBITDA, excluding non-recurring items, was SEK 3,183 million against SEK 1,961 million, corresponding to an increase of 62%, and a margin of 32.7% against 28.7% a year ago. Non-recurring effects had a SEK 308 million negative impact on earnings before tax. Profit after tax amounted to SEK 618 million against SEK 503 million a year ago. Earnings per share reached SEK 1.69 against SEK 1.60 a year ago. Excluding non-recurring effects, earnings per share totaled SEK 1.93 against SEK 1.47 a year ago. Cash earnings per share amounted to SEK 1.57 against SEK 3.99 a year ago. Excluding non-recurring effects cash earnings per share totaled SEK 3.92 against SEK 3.99 a year ago. For the quarter, the company reported net sales reached SEK 5,152 million against SEK 3,477 million a year ago, corresponding to an increase of 48%, 38% at constant exchange rates compared to the previous year. EBITDA, excluding non-recurring items, was SEK 1,780 million against SEK 951 million, corresponding to an increase of 87%, yielding a 34.5% margin against 27.4% a year ago. Non-recurring effects had a SEK 90 million negative impact on earnings before tax. Profit after tax amounted to SEK 392 million against SEK 243 million a year ago. Earnings per share reached SEK 1.07 against SEK 0.77 a year ago. Excluding non-recurring effects, earnings per share totaled SEK 1.34 against SEK 0.64 a year ago. Cash earnings per share amounted to SEK 0.83 against SEK 2.09 a year ago. Excluding non-recurring effects cash earnings per share totaled SEK 1.98 against SEK 2.09 a year ago.

Meda AB, Q2 2015 Earnings Call, Jul 23, 2015

Meda AB, Q2 2015 Earnings Call, Jul 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEDAA:SS kr127.60 SEK -2.60

MEDAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.132.30 CHF -1.20
Astellas Pharma Inc ¥1,666 JPY -34.50
H Lundbeck A/S kr194.00 DKK -5.40
Moberg Pharma AB kr57.00 SEK -1.25
Shire PLC 4,856 GBp -43.00
View Industry Companies
 

Industry Analysis

MEDAA

Industry Average

Valuation MEDAA Industry Range
Price/Earnings 83.5x
Price/Sales 2.5x
Price/Book 2.2x
Price/Cash Flow 87.4x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDA AB-A SHS, please visit www.meda.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.